CRDL adds US$11M financing, cash runway into Q3 2027

Rhea-AI Filing Summary

Cardiol Therapeutics (CRDL) furnished a Form 6‑K that includes a news release titled “Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027.” The filing signals that the company has secured US$11 million in financing, which the company states extends its cash runway into Q3 2027. Details of the structure or terms are contained in the referenced news release.

Insights

Biotech capital markets analyst

US$11M financing extends cash runway into Q3 2027.

Cardiol Therapeutics reports securing US$11,000,000 in financing, with the company stating its runway now extends into Q3 2027. For development‑stage biopharma, extending runway helps maintain program continuity and supports operating plans.

Actual effects depend on specific financing terms and timing, which are referenced in the accompanying news release. The headline points to added liquidity through Q3 2027, indicating near‑term funding visibility.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated October 17, 2025 - Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: October 17, 2025	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer

FAQ

What did Cardiol Therapeutics (CRDL) announce in its Form 6-K?

The company furnished a news release stating it secured US$11 million in financing and extended its cash runway into Q3 2027.

How much financing did CRDL secure?

The news release states US$11 million in financing.

How long does CRDL’s cash runway extend according to the news release?

The company states its cash runway extends into Q3 2027.

What document type did Cardiol Therapeutics file?

A Form 6‑K, reporting a news release to investors.

Where can I find the details of the financing terms for CRDL?

The terms are in the furnished news release titled “Secures US$11 Million Financing and Extends Cash Runway into Q3 2027.”